William Blair analyst Sami Corwin has maintained their bullish stance on RCKT stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sami Corwin has given his Buy rating due to a combination of factors that highlight Rocket Pharmaceuticals’ promising future. The recent acceptance of the BLA resubmission for Kresladi by the FDA marks a significant milestone, setting a PDUFA date for March 28, 2026. This acceptance comes after addressing previous concerns related to chemistry and manufacturing controls, indicating a positive trajectory for the company’s gene therapy program.
Furthermore, the data from the global Phase I/II study supports the potential of Kresladi, showing sustained CD18 restoration and 100% survival at 1.5 years. The potential approval of Kresladi could earn Rocket a rare pediatric disease priority review voucher, providing substantial non-dilutive revenue. Despite the company’s focus on its late-stage AAV pipeline, the anticipated launch of Kresladi in the third quarter of 2026 and projected peak sales reinforce the Buy rating.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $16.00 price target.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is neutral on the stock.